Where is Antev located?

Antev is headquartered in London, United Kingdom. It is registered at 3RD FLOOR, 106,NEW BOND STREET,LONDON,ENGLAND,W1S 1DN.

How many employees does Antev have?

As of May 31, 2026, the latest employee count at Antev is 6.

Is Antev a funded company?

Antev is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Antev rank among its competitors?

Antev ranks 3rd amongst 21 active competitors, of which 7 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Lipella, which secured $1.35M in Aug, 2025.

Who are the top competitors of Antev?

Antev's top competitors include Lipella, Kissei Pharmaceutical and NEXT Life Sciences. Among them, Lipella secured the most recent funding round in August, 2025.

Antev - 2026 Company Profile, Team, Competitors & Financials

Q: Is Antev an acquired company?

Antev got acquired by Medicus Pharma on Apr 28, 2025.

Company Details

Antev is a biotechnology company with a focus on urology. The company's flagship products are based on a technology called as Teverelix, a patented and proprietary long-acting GnRH (gonadotrophin releasing hormone) antagonist and targeted for the indications of benign prostatic hyperplasia and acute urinary retention. Teverelix has completed phase II & is ready to undergo phase III trials for benign prostatic hyperplasia, prostate cancer & phase I for endometriosis. The company is also trying to useTeverelix for veterinary applications.

Website: antev.co.uk
Email ID: *****@antev.co.uk
Registered Address: 3RD FLOOR, 106,NEW BOND STREET,LONDON,ENGLAND,W1S 1DN

Key Metrics

Founded Year

2013

Location

London, United Kingdom

Stage

Acquired

Ranked

3^rd among 21 active competitors

Employee Count

6 as on May 31, 2026

Similar Companies

Lipella & 27 more

Exit Details

Acquired by Medicus Pharma (Apr 28, 2025)

View Antev's full profile

Antev is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Antev Limited CIN: 8764600 , United Kingdom, Active	Nov 05, 2013	-	8 (As on Dec 31, 2024)

Antev got acquired by Medicus Pharma on Apr 28, 2025 at an acquisition amount of $*****.

Click here to take a look at Antev's acquisition in detail

Antev is a funded company.

The founders of Antev is Oliver Bates.

Here are the details of Antev's key team members:

Oliver Bates: Co-Founder & Director of Antev.

View details of Antev's Founder profiles and Board Members

Antev's employee count trend

Antev has 6 employees as of May 26. Here is Antev's employee count trend over the years:

Uncover Antev's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Antev include Lipella, Kissei Pharmaceutical and NEXT Life Sciences. Here is the list of Top 10 competitors of Antev, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lipella 2005, Pittsburgh (United States), Public	Developer of lipid-based therapies for common bladder syndromes	$3.37M	Military Health, HHS	58/100
2nd	Kissei Pharmaceutical 1946, Matsumoto (Japan), Public	Developer of therapies for treating renal diseases and urology related anaemia	-	-	57/100
3rd	Antev 2013, London (United Kingdom), Acquired	GnRH antagonists for urology indications in humans & animals	-	-	50/100
4th	NEXT Life Sciences 2021, San Luis Obispo (United States), Seed	Developer of male contraception procedures	$4.05M	Transform VC, The Family & 8 others	50/100
5th	Regrow 2009, Mumbai (India), Seed	Provider of autologous cell therapy for tissue repair and stem cell banking services	$2.84M	Ascus International, Satyan Pharmaceuticals ... & 7 others	44/100
6th	Esprit Pharma 2005, East Brunswick (United States), Acquired	Develop drugs for genitourinary (GU) disorders	$219M	Apax, Domain Associates & 5 others	44/100
7th	LTR Pharma 2020, Brisbane (Australia), Public	Developer of therapeutics for the treatment of erectile dysfunction	-	-	42/100
8th	Urigen Pharmaceuticals 1997, North Brunswick (United States), Series A	Developer of pain relief products for patients with urological ailments	$6.05M	-	40/100
9th	Sumitomo 2017, Irvine (United States), Public	Developer of therapies for treating urological disorders	-	Hercules Capital, Sumitovant	38/100
10th	Acerus Pharma 2008, Mississauga (Canada), Deadpooled	Developing drugs for treating urology, hormone replacement therapy & female sexual dysfunction	$27.6M	SWK Holdings, MidCap Financial & 2 others	37/100